Welcome to our dedicated page for Instil Bio news (Ticker: TIL), a resource for investors and traders seeking the latest updates and insights on Instil Bio stock.
Instil Bio, Inc. (Nasdaq: TIL) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of autologous tumor infiltrating lymphocyte (TIL) therapies to treat patients with cancer. The company's core technology leverages a patient’s own T cells, harvested from their tumor, expanded in number, and then reinfused to target and kill cancer cells. This innovative approach is designed to harness and enhance the body’s natural defense mechanisms to fight solid tumor cancers.
Headquartered in the greater Los Angeles area, Instil Bio also has a significant presence in Manchester, UK, where it houses additional manufacturing and research facilities. This strategic international footprint enables the company to execute clinical trials globally, advancing its pipeline of novel TIL therapies.
Instil Bio is currently focused on its lead candidate, ITIL-306, a next-generation, genetically-engineered TIL therapy using its proprietary Co-Stimulatory Antigen Receptor (CoStAR™) platform. ITIL-306 is designed to target a tumor-associated antigen FRα, prevalent in various solid tumors including ovarian, uterine, non-small cell lung cancer (NSCLC), and renal cancers. The company is actively progressing this candidate through clinical trials, with promising preclinical data supporting its potential efficacy.
Recent Achievements:
- June 26, 2023: Instil Bio presented data at the British Society for Gene and Cell Therapy Annual Conference, showcasing the enhanced activity of TILs using the CoStAR platform against autologous tumors.
- August 14, 2023: Reported successful manufacturing improvements at its Manchester facility, which could significantly impact the therapeutic profile of ITIL-306 in patients with advanced cancers.
Financial Condition:
As of the latest reports, Instil Bio has a solid financial foundation with cash, cash equivalents, marketable securities, and long-term investments enabling the company to fund its operations beyond 2026. Despite typical R&D and administrative expenses associated with a clinical-stage company, Instil has managed to maintain a stable financial position to propel further developments.
Partnerships and Collaborations:
Instil Bio is supported by premier global institutional investors and is led by a team of world-class cell therapy experts. These partnerships bolster the company’s capability to innovate and bring transformative therapies to market.
Instil Bio’s strategic focus on cutting-edge TIL therapies, robust financial health, and innovative research make it a significant player in the biopharmaceutical landscape, with great potential to bring effective cancer treatments to patients worldwide.
Instil Bio reported Q3 2024 financial results and corporate updates. The company licensed SYN-2510, a PD-L1xVEGF bispecific antibody, for global ex-China development. Cash position was $122.9M as of September 30, 2024, expected to fund operations beyond 2026. Q3 net loss per share was $3.54. Clinical updates include anticipated data from ImmuneOnco for SYN-2510 in 1H 2025, planned Phase 1b/2 studies in NSCLC and TNBC, and targeted U.S. clinical study initiation in 2H 2025.
Instil Bio (Nasdaq: TIL) and ImmuneOnco Biopharmaceuticals have announced their global registrational strategy for the PD-L1xVEGF bispecific antibody SYN-2510/IMM2510 in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Key points include:
1. Phase 1b/2 trials of IMM2510/SYN-2510 + chemotherapy in first-line NSCLC to start in China by late 2024
2. Phase 1b/2 trials in first-line TNBC to begin in China by early 2025
3. US IND submission for SYN-2510 planned for late 2024, starting with Phase 2 monotherapy trial in second-line NSCLC
4. Potential global Phase 3 trials in first-line NSCLC and TNBC based on positive proof-of-concept data
This strategy aims to address significant unmet medical needs in NSCLC and TNBC patients, potentially improving the current standard of care.
Instil Bio (Nasdaq: TIL) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
1. In-licensed SYN-2510 and SYN-27M, potentially best-in-class therapeutics, from ImmuneOnco.
2. Executed a 15-year lease of cell therapy manufacturing facility to AstraZeneca, with initial base rent exceeding $7.5 million annually.
3. Cash, cash equivalents, marketable securities, and long-term investments totaled $152.6 million as of June 30, 2024.
4. Q2 2024 R&D expenses were $2.9 million, down from $8.5 million in Q2 2023.
5. Net loss per share for Q2 2024 was $2.29, improved from $2.87 in Q2 2023.
6. Cash runway expected to extend beyond 2026.
Instil Bio (Nasdaq: TIL) and ImmuneOnco Biopharmaceuticals have announced a license and collaboration agreement for the development of two promising antibodies: IMM2510 and IMM27M. IMM2510 is a potentially best-in-class PD-L1xVEGF bispecific antibody that has shown multiple responses in advanced solid tumors, including in patients who previously failed PD-1 inhibitors. IMM27M is a novel next-generation anti-CTLA-4 antibody designed to enhance efficacy and reduce toxicity compared to first-generation anti-CTLA-4 antibodies.
Under the agreement, Instil Bio will receive global development and commercialization rights for both antibodies outside of Greater China, while ImmuneOnco retains rights in Greater China. The deal includes an upfront payment and potential near-term payments of up to $50 million, with additional milestones exceeding $2 billion plus royalties on global ex-China sales.
Instil Bio, Inc. reported its first quarter 2024 financial results, showcasing a cash balance of $161.5 million, expected to fund operations beyond 2026. The company highlighted successful feasibility studies, plans for a potential trial in non-small cell lung cancer, and exploring new therapeutic candidates. Research and development expenses decreased, while general and administrative expenses remained stable. Non-GAAP net loss per share improved from the previous year.
FAQ
What is the current stock price of Instil Bio (TIL)?
What is the market cap of Instil Bio (TIL)?
What is Instil Bio’s primary focus?
What is the CoStAR™ platform?
Where is Instil Bio headquartered?
What is ITIL-306?
What recent milestones has Instil Bio achieved?
How is Instil Bio’s financial health?
Who leads Instil Bio?
What cancers does ITIL-306 target?
What are TIL therapies?
How does Instil Bio enhance TIL therapies?
